|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Melanoma (Skin) | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Melanoma | |||||
| 3 | More general conditions related to this trial | ||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| Neoplasms, Germ Cell and Embryonal | |||||
| Neoplasms, Nerve Tissue | |||||
| Neuroectodermal Tumors | |||||
| Neuroendocrine Tumors | |||||
| Nevi and Melanomas | |||||
| 4 | Interventions listed in this trial | ||||
| GM2-KLH vaccine | |||||
| QS21 | |||||
| adjuvant therapy | |||||
| 5 | Sponsors listed in this trial | ||||
| European Organization for Research and Treatment of Cancer | |||||